Erratum: Corrigendum to “Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction” (Journal of Cardiac Failure (2016) 22(6) (423–432)(S1071916416000671)(10.1016/j.cardfail.2016.02.007))

  • Yuya Matsue
  • , Makoto Suzuki
  • , Sho Torii
  • , Satoshi Yamaguchi
  • , Seiji Fukamizu
  • , Yuichi Ono
  • , Hiroyuki Fujii
  • , Takeshi Kitai
  • , Toshihiko Nishioka
  • , Kaoru Sugi
  • , Yuko Onishi
  • , Makoto Noda
  • , Nobuyuki Kagiyama
  • , Yasuhiro Satoh
  • , Kazuki Yoshida
  • , Steven R. Goldsmith

Research output: Contribution to journalComment/debatepeer-review

4 Scopus citations

Abstract

The authors regret that on page 429, in the Discussion section of the Aquamarine trial, the ASCEND trial is incorrectly described. The actual title is ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). The reference (21) is correct. Also on page 429, the RELAX-AHF trial is incorrectly cited. The correct trial referred to is PROTECT. Reference 22 should be: Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, et al, PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-28. The authors apologize for any inconvenience caused.

Original languageEnglish (US)
Pages (from-to)941
Number of pages1
JournalJournal of cardiac failure
Volume22
Issue number11
DOIs
StatePublished - Nov 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier Inc.

Fingerprint

Dive into the research topics of 'Erratum: Corrigendum to “Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction” (Journal of Cardiac Failure (2016) 22(6) (423–432)(S1071916416000671)(10.1016/j.cardfail.2016.02.007))'. Together they form a unique fingerprint.

Cite this